128 related articles for article (PubMed ID: 30273512)
1. A simple and safe antibody neutralization assay based on polio pseudoviruses.
Jiang Z; Liu G; Guo-Yang L; Sun M; Xu K; Ying Z; Wang J; Li X; Li C
Hum Vaccin Immunother; 2019; 15(2):349-357. PubMed ID: 30273512
[TBL] [Abstract][Full Text] [Related]
2. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model.
Bockstal V; Tiemessen MM; Achterberg R; Van Wordragen C; Knaapen AM; Serroyen J; Marissen WE; Schuitemaker H; Zahn R
Vaccine; 2018 Nov; 36(46):6979-6987. PubMed ID: 30314910
[TBL] [Abstract][Full Text] [Related]
3. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains.
Kersten G; Hazendonk T; Beuvery C
Vaccine; 1999 Apr; 17(15-16):2059-66. PubMed ID: 10217607
[TBL] [Abstract][Full Text] [Related]
4. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine.
Hotta C; Ogawa T; Shirasawa H
Hum Vaccin Immunother; 2019; 15(5):1154-1159. PubMed ID: 30676843
[TBL] [Abstract][Full Text] [Related]
5. Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains.
Westdijk J; Koedam P; Barro M; Steil BP; Collin N; Vedvick TS; Bakker WA; van der Ley P; Kersten G
Vaccine; 2013 Feb; 31(9):1298-304. PubMed ID: 23313617
[TBL] [Abstract][Full Text] [Related]
6. Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats.
Ma L; Cai W; Sun M; Cun Y; Zhou J; Liu J; Hu W; Zhang X; Song S; Jiang S; Liao G
Hum Vaccin Immunother; 2016 Dec; 12(12):3125-3131. PubMed ID: 27558963
[TBL] [Abstract][Full Text] [Related]
7. A safe and reliable neutralization assay based on pseudovirus to measure neutralizing antibody titer against poliovirus.
Liu S; Song D; Bai H; Lu W; Dai X; Hao C; Zhang Z; Guo H; Zhang Y; Li X
J Med Virol; 2017 Dec; 89(12):2075-2083. PubMed ID: 28786502
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
Verdijk P; Rots NY; van Oijen MG; Oberste MS; Boog CJ; Okayasu H; Sutter RW; Bakker WA
Vaccine; 2013 Nov; 31(47):5531-6. PubMed ID: 24063976
[TBL] [Abstract][Full Text] [Related]
9. Development of a poliovirus neutralization test with poliovirus pseudovirus for measurement of neutralizing antibody titer in human serum.
Arita M; Iwai M; Wakita T; Shimizu H
Clin Vaccine Immunol; 2011 Nov; 18(11):1889-94. PubMed ID: 21880850
[TBL] [Abstract][Full Text] [Related]
10. Effects of the thermal denaturation of Sabin-derived inactivated polio vaccines on the D-antigenicity and the immunogenicity in rats.
Murakami K; Fujii Y; Someya Y
Vaccine; 2020 Apr; 38(17):3295-3299. PubMed ID: 32197923
[TBL] [Abstract][Full Text] [Related]
11. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains.
Tano Y; Shimizu H; Martin J; Nishimura Y; Simizu B; Miyamura T
Vaccine; 2007 Oct; 25(41):7041-6. PubMed ID: 17825459
[TBL] [Abstract][Full Text] [Related]
12. A novel multiplex poliovirus binding inhibition assay applicable for large serosurveillance and vaccine studies, without the use of live poliovirus.
Schepp RM; Berbers GA; Ferreira JA; Reimerink JH; van der Klis FR
J Virol Methods; 2017 Mar; 241():15-23. PubMed ID: 27988324
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
[TBL] [Abstract][Full Text] [Related]
14. Intranasal and sublingual delivery of inactivated polio vaccine.
Kraan H; Soema P; Amorij JP; Kersten G
Vaccine; 2017 May; 35(20):2647-2653. PubMed ID: 28400164
[TBL] [Abstract][Full Text] [Related]
15. [Immunogenicity of sabin inactivated poliovirus vaccine induced by diphtheria-tetanus-acellular pertussis and Sabin inactivated poliovirus combined vaccine].
Ma Y; Qin M; Hu HQ; Ji G; Feng L; Gao N; Gu J; Xie BF; He JH; Sun MB
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Jun; 25(3):197-200. PubMed ID: 21977591
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of antigenic differences between wild and Sabin vaccine strains of poliovirus using the pseudovirus neutralization test.
Arita M; Iwai-Itamochi M
Sci Rep; 2019 Aug; 9(1):11970. PubMed ID: 31427704
[TBL] [Abstract][Full Text] [Related]
17. [Comparing the immunogenicity and safety of sequential inoculation of sIPV followed by bOPV (Ⅰ+Ⅲ) in different dosage forms].
Ye H; Huang T; Ying ZF; Li GL; Che YC; Zhao ZM; Wang JF; Yang XL; Shi L; Jiang RJ; Liu XC; Mo ZJ; Li CG; Yang JS
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jan; 52(1):43-49. PubMed ID: 29334707
[No Abstract] [Full Text] [Related]
18. Progress with inactivated poliovirus vaccines derived from the Sabin strains.
Doi Y; Abe S; Yamamoto H; Horie H; Ohyama H; Satoh K; Tano Y; Ota Y; Miyazawa M; Wakabayashi K; Hashizume S
Dev Biol (Basel); 2001; 105():163-9. PubMed ID: 11763324
[TBL] [Abstract][Full Text] [Related]
19. A national reference for inactivated polio vaccine derived from Sabin strains in Japan.
Shirato H; Someya Y; Ochiai M; Horiuchi Y; Takahashi M; Takeda N; Wakabayashi K; Ouchi Y; Ota Y; Tano Y; Abe S; Yamazaki S; Wakita T;
Vaccine; 2014 Sep; 32(40):5163-9. PubMed ID: 25090648
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the neutralizing activities of antibodies in clinical sera against both Sabin and wild-type polio pseudoviruses.
Liu S; Lu W; Ma S; Guo H; Zhang Z; Li X
J Virol Methods; 2022 Feb; 300():114376. PubMed ID: 34826519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]